Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrei Thomas-Tikhonenko

Showing results (1-10 of 78) with videos related to

Pageof 8
Sort By:
Cancer Treatment and Research|April 14, 2006
Infection & neoplastic growth 101: the required reading for microbial pathogens aspiring to cause cancerJessica Bertout, Andrei Thomas-Tikhonenko
Cancer Biology & Therapy|June 9, 2006
Kit-activating mutations in AML: lessons from PU.1-induced murine erythroleukemiaDiana Cozma, Andrei Thomas-Tikhonenko
Pharmacology & Therapeutics|April 26, 2011
Shielding the messenger (RNA): microRNA-based anticancer therapiesElena Sotillo, Andrei Thomas-Tikhonenko
Oncogene|March 16, 2002
A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesisDuonan Yu, Andrei Thomas-Tikhonenko
Trends in Cancer|November 25, 2018
Exons of Leukemia Suppressor Genes: Creative Assembly RequiredMukta Asnani, Andrei Thomas-Tikhonenko
Cytokine & Growth Factor Reviews|December 18, 2002
Infection and cancer: the common veinAndrei Thomas-Tikhonenko, Christopher A Hunter
Cold Spring Harbor Perspectives in Medicine|April 17, 2014
MYC and the art of microRNA maintenanceJames N Psathas, Andrei Thomas-Tikhonenko
The Journal of Clinical Investigation|September 15, 2021
RNA-binding proteins of COSMIC importance in cancerPeter S Choi, Andrei Thomas-Tikhonenko
Blood|February 8, 2007
p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitorsDuonan Yu, Martin Carroll, Andrei Thomas-Tikhonenko
Cancer Journal (Sudbury, Mass.)|May 29, 2019
Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen ReceptorsSisi Zheng, Mukta Asnani, Andrei Thomas-Tikhonenko
Pageof 8

Showing results (1-10 of 78) with videos related to

Sort By:
Pageof 8
Cancer Treatment and Research|April 14, 2006
Infection & neoplastic growth 101: the required reading for microbial pathogens aspiring to cause cancerJessica Bertout, Andrei Thomas-Tikhonenko
Cancer Biology & Therapy|June 9, 2006
Kit-activating mutations in AML: lessons from PU.1-induced murine erythroleukemiaDiana Cozma, Andrei Thomas-Tikhonenko
Pharmacology & Therapeutics|April 26, 2011
Shielding the messenger (RNA): microRNA-based anticancer therapiesElena Sotillo, Andrei Thomas-Tikhonenko
Oncogene|March 16, 2002
A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesisDuonan Yu, Andrei Thomas-Tikhonenko
Trends in Cancer|November 25, 2018
Exons of Leukemia Suppressor Genes: Creative Assembly RequiredMukta Asnani, Andrei Thomas-Tikhonenko
Cytokine & Growth Factor Reviews|December 18, 2002
Infection and cancer: the common veinAndrei Thomas-Tikhonenko, Christopher A Hunter
Cold Spring Harbor Perspectives in Medicine|April 17, 2014
MYC and the art of microRNA maintenanceJames N Psathas, Andrei Thomas-Tikhonenko
The Journal of Clinical Investigation|September 15, 2021
RNA-binding proteins of COSMIC importance in cancerPeter S Choi, Andrei Thomas-Tikhonenko
Blood|February 8, 2007
p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitorsDuonan Yu, Martin Carroll, Andrei Thomas-Tikhonenko
Cancer Journal (Sudbury, Mass.)|May 29, 2019
Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen ReceptorsSisi Zheng, Mukta Asnani, Andrei Thomas-Tikhonenko
Pageof 8